Systemic manifestations of the pseudoexfoliation

Tatjana S Sarenac; Dejan D Vulovic; Sladjana M Pavlovic; Sladjana Simovic; Nemanja S Zdravkovic; Mirjana A Janicijevic-Petrovic

doi:10.5937/sjecr15-5020

Tatjana S Sarenac Clinic of ophthalmology, Clinical Centre Kragujevac
Dejan D Vulovic Centre for plastic and reconstructive surgery, Clinical Centre Kragujevac
Sladjana M Pavlovic Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac
Sladjana Simovic Health Centre ENP department Kragujevac
Nemanja S Zdravkovic Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac
Mirjana A Janicijevic-Petrovic Clinic of ophthalmology, Clinical Centre Kragujevac

DOI: https://doi.org/10.5937/sjecr15-5020

Abstract

Objective:

The aim of our study was to establish correlation between pseudoexfoliation and its systemic manifestation.

Findings:

Pseudoexfoliation syndrome is an age related systemic disorder with overproduction and accumulation of the pseudoexfoliation material in visceral organs and in the eye. Many vascular diseases are in tight junction with pseudoexfoliation manifestation. Arterial hypertension was equally represented in all selected groups. Our results indicated for statistical significant differences in the number of patients with ischemic cardiac disease, cerebrovascular disease, presence of aortal aneurism or sensoneurial hear loss in PEX group (syndrome or glaucoma) in comparison with patients in control group. There were no statistical significant differences between two subgroups of PEX group (syndrome, glaucoma). This result indicated that the main risk for systemic manifestation is PEX presence. Other ocular and vascular complications are PEX consequences.

Conclusion:

Pseudoexfoliation is in tight relation with systemic vascular disturbances. Patients with PXS must be detailed examined by specialist of internal disease or neurologist. Those recommended examination can be helpful in prevention of hard vascular disease of the patients with PEX, especially with early stage.

References

Schlotzer-Schrehardt U, Naumann GO: Ocular and systemic pseudoexfoliation syndrome. Am J Ophthalmol 2006; 141: 921–37.

Schlotzer-Schrehardt UM, Koca MR, Naumann GO, Volkholz H: Pseudoexfoliation syndrome. Ocular manifestation of a systemic disorder? Arch Ophthalmol 1992; 110: 1752–6.

Streeten BW, Li ZY, Wallace RN, Eagle RC Jr, Keshgegian AA: Pseudoexfoliative fibrillopathy in visceral organs of a patient with pseudoexfoliation syndrome. Arch Ophthalmol 1992; 110: 1757–62.

Ritch R, Schlotzer-Schrehardt U. Exfoliation syndrome. Surv Ophthalmol 2001; 45: 263-315.

Mitchell P, Wang JJ, Smith W. Association of pseudoexfoliation syndrome with increased vascular risk. Am J Ophthalmol 1997; 124: 685-7.

Mitchell P, Wang JJ, Hourihan F. The relatioship between glaucoma and pseudoexfoliation. The blue mountains eye study. Arch Ophthalmol 1999; 117:1319-24.

Naumann GO, Schlotzer-Schrehardt U, Kuchle M. Pseudoexfoliation syndrome for the comprehensive ophthalmologist. Intraocular ans systemic manifestation. Ophthalmology 1998; 105: 951-68.

Koliakos GG, Konstas AG, Triantos A, Ritch R. Increased growth factor activity in the aqueous humor of patients with exfoliation syndrome. Graefe’s Arch Clin Exp Ophthalmol 2000; 38: 491-5.

Eyries M, Collins T, Khachigian LM. Modulation of growth factor gene expression in vascular cells by oxidative stress. Endothelium 2004; 11:133-9.

Ho SL, Dogar GF, Wang J, Crean J, Wu QD, Oliver N, Weitz S, Murray A, Cleary PE, O’Brien C. Elevated aqueous humor tissue inhibitor of matrix metalloproteinase-1 and connective tissue growth factor in pseudoexfoliation syndrome. Br J Ophthalmol 2005; 89:169-73.

Bleich S, Roedl J, Von Ahsen N, Schlotzer-Schrehardt U, Reulbach U, Beck G et all. Elevated homocysteine levels in aqueous humor of patients with pseudoexfoliation glaucoma. Am J Ophthalmol 2004; 138:162-4.

Praveen MR, Shah SK, Vasavada AR, Diwan RP, Shah SM, Zumkhawala BR,R Thomas R. Pseudoexfoliation as a risk factor for peripheral vascular disease: a case control study. Eye 2011; 2: 174–9.

Repo LP, Terasvirta ME, Tuovinen EJ. Generalized peripheral iris transluminance in the pseudoexfoliation syndrome. Ophthalmology 1990; 97: 1027–9.

Helbig H, Schlotzer-Schrehardt U, Noske W, Kellner U, Foerster MH, Naumann GO. Anterior-chamber hypoxia and iris vasculopathy in pseudoexfoliation syndrome. Ger j Ophthalmol 1994; 3: 148-53.

Parodi MB, Bondel E, Saviano S, ravalico G. Iris indocyanine green angiography in pseudoexfoliation syndrome and capsular glaucoma. Acta Ophthalmol Scand 2000; 78: 437-42.

Hollo G, Lakatos P, farkas K. Cold pressor test and plasma endothelin-1 concentration in primary open angle and capsular glaucoma. J Glaucoma 1998; 7: 105-10.

Lim DJ. Functional Structure of the organ of corti: a review. Hear res, 1986; 22: 117-46

Yazdani Sh, Tousi A, Pakravan M, Faghihi AR. Sensorineural Hearing Loss in Pseudoexfoliation Syndrome. Ophthalmology 2008;115: 425-9.